Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen

Day One Biopharmaceuticals (NASDAQ:DAWN) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Other equities analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and issued a $21.50 target price (down from $30.00) on shares of Day One Biopharmaceuticals in a report on Monday, March 9th. TD Cowen lowered shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 6th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday, March 6th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $21.50 target price (down from $27.00) on shares of Day One Biopharmaceuticals in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Hold” and an average price target of $23.29.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $21.53 on Friday. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $21.53. The firm has a market cap of $2.22 billion, a P/E ratio of -20.90 and a beta of -1.74. The company’s 50-day moving average price is $18.63 and its two-hundred day moving average price is $12.50.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Equities analysts predict that Day One Biopharmaceuticals will post -0.86 EPS for the current year.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer directly owned 312,025 shares in the company, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Vasconcelles sold 2,728 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares in the company, valued at approximately $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,461 shares of company stock worth $422,948 in the last quarter. Corporate insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $10,719,000. AlphaQuest LLC boosted its position in Day One Biopharmaceuticals by 1,065.6% during the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock worth $1,304,000 after buying an additional 169,134 shares during the period. Mak Capital One LLC acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $10,212,000. Hennion & Walsh Asset Management Inc. boosted its position in Day One Biopharmaceuticals by 229.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,455 shares of the company’s stock worth $2,921,000 after buying an additional 218,383 shares during the period. Finally, Algert Global LLC boosted its position in Day One Biopharmaceuticals by 45.4% during the 3rd quarter. Algert Global LLC now owns 1,317,042 shares of the company’s stock worth $9,285,000 after buying an additional 411,000 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.